Medical technologies
-
New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
Data presented have been submitted to U.S. and EU regulatory agencies and represent an important step towards addressing the high unmet need in this patient population -
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH 2020 -
Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
Combined results from Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 show 97 percent overall response rate at median follow-up of 12.4 months -
-
ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Final analysis of the Phase 3 SPARTAN study presented during ASCO Virtual Scientific Program suggests 14-month improvement in median overall survival -
Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation
PRECEPT study demonstrated 15-month freedom from symptomatic persistent atrial fibrillation in 80.4 percent of patients who underwent cardiac ablation using THERMOCOOL SMARTTOUCH® SF Catheter1 -
Ethicon Launches VISTASEAL Fibrin Sealant (Human) to Manage Bleeding During Surgery
Next Generation Device Simplifies Setup and May Save Valuable Operating Room Time VISTASEAL is first innovation to emerge from Ethicon’s strategic partnership with Grifols, a pioneer in the plasma industry -
Auris Health Announces Late-Breaking Results from First-in-Human Study of Monarch™ Platform
Data Presented at CHEST 2019 Demonstrates Efficacy of Monarch to Successfully Reach Nodules and Biopsy Tissue -
Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide)
Stay informed with the latest results from the SPARTAN study, showcasing a significant 25% reduction in the risk of death for prostate cancer patients.